Pages
Home
MIDDLE EAST
AFRICA
Sunday, 22 November 2020
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine. - GlobeNewswire
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
GlobeNewswire
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment